By Rishabh Jaiswal and Sabrina Valle (Reuters) -Obesity drug developer Metsera has accepted Pfizer's $10 billion acquisition ...

Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a ...

By Rishabh Jaiswal and Sabrina Valle (Reuters) -Obesity drug developer Metsera said on Friday that it had accepted Pfizer's ...

Earlier this year, Pfizer shelved a clinical trial for its own weight-loss drug candidate amid safety concerns and shifted ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drug maker, Metsera decided to side with its original suitor.

Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer ...

Obesity drug developer Metsera said on Friday that it had accepted Pfizer's $10 billion acquisition offer, in what could ...

(Reuters) -Pfizer has submitted a sweetened bid for obesity drug developer Metsera, as its fight against rival Novo Nordisk ...

NEW YORK/LONDON (Reuters) -A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker ...

Republican Chairman Ron Johnson excoriated ranking member Richard Blumenthal in a sprawling rant that transformed the hearing ...